Meridian Bioscience, Inc., will begin production of recombinant Trypanosoma cruzi (Chagas’ disease) antigen under a license agreement with Corixa Corporation. Manufacture will take place in its life science production laboratories located at Viral Antigens, Inc., (VAI), a wholly owned subsidiary.
The unique recombinant polyvalent antigen, known as TcF, will be marketed to diagnostic test manufacturers for use in production of test kits for blood bank screening and other diagnostic applications.
T. cruzi causes Chagas’ disease, a chronic infection that primarily affects the nervous system and heart, causing severe neurological disorders, as well as swelling or denervation of nervous tissue in the heart, colon and esophagus.
Richard Eberly, General Manager, Meridian Life Science commented, “We are delighted that VAI’s original research and development agreement with Corixa has now resulted in a strategic partnership to make this important antigen available for commercialization partners. We are pleased that VAI will now make this antigen available to manufacturers worldwide for incorporation into test kits to improve the safety of the blood supply.”
David Persing, M.D., Ph.D., Vice President of Discovery Research at Corixa, said recently “In studies to date, the TcF recombinant antigen has been able to detect specific antibodies in nearly all patients infected with T. cruzi, and avoids many of the problems of false positivity and unreliability associated with older assays that used whole organisms for antibody detection. Testing for this antibody could be an important step toward protecting our nation’s blood supply from this dangerous contaminant.”
Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system.
Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and